Clinical Trial Update: A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update evaluating APG-1252 in combination with osimertinib for EGFR TKI-resistant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• APG-1252 (APG-1252)
• Osimertinib (osimertinib)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: EGFR Positive Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING